lilotomab   Click here for help

GtoPdb Ligand ID: 9950

Synonyms: Betalutin® | HH1 | tetulomab
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lilotomab is an investigational murine anti-CD37 monoclonal antibody [1]. A radioimmunoconjugate version that can be loaded with the beta radiation-emitting isotope lutetium-177 (known as 177Lu-lilotomab satetraxetan, and as the trade name Betalutin) is being evaluated as a novel radioimmunotherapeutic for the treatment of non-Hodgkin lymphoma [2]. Satetraxetan is the name of the radionuclide chelator, and this is a DOTA derivative known as (p-SCN-Bn)-DOTA (PubChem CID 10123265).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
CD37 is an immuno-oncology target that is being evaluated for the treatment of B cell malignancies, including non-Hodgkin lymphoma and CLL.
Immunopharmacology Disease
Disease X-Refs Comment References
non-Hodgkin lymphoma Disease Ontology: DOID:0060060
OMIM: 605027
 A first-in-human phase 1/2a study for relapsed CD37+ve indolent NHL determined that predosing with 'cold' lilotomab resulted in a more favourable ratio of labelled lilotomab being adsorbed to tumour cells rather than to red marrow (which is a dose-limiting site of biodistribution for 177Lu-lilotomab satetraxetan treatment). 2
Diffuse large B-cell lymphoma Disease Ontology: DOID:0050745
 177Lu-lilotomab satetraxetan is a Phase 1 clinical candidate for relapsed/refractory DLBCL- see NCT02658968.